Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Galimberti, Sara, Petrini, Mario, Baratè, Claudia, Ricci, Federica, Balducci, Serena, Grassi, Susanna, Guerrini, Francesca, Ciabatti, Elena, Mechelli, Sandra, Di Paolo, Antonello, Baldini, Chiara, Baglietto, Laura, Macera, Lisa, Spezia, Pietro Giorgio, Maggi, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493657/
https://www.ncbi.nlm.nih.gov/pubmed/33014780
http://dx.doi.org/10.3389/fonc.2020.01428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493657/
https://www.ncbi.nlm.nih.gov/pubmed/33014780
http://dx.doi.org/10.3389/fonc.2020.01428

Ejemplares similares